A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE)
Phase of Trial: Phase II
Latest Information Update: 28 Jun 2017
At a glance
- Drugs MSDC 0602 (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Therapeutic Use
- Acronyms EMMINENCE
- Sponsors Cirius Therapeutics
- 11 Apr 2017 According to a Cirius Therapeutics media release, this trial was initiated by Octeta Therapeutics , but later on this company's name changed to Cirius Therapeutics.
- 11 Apr 2017 According to a Cirius Therapeutics media release, company announced the completion of a Series A financing of up to $40 million led by Frazier Healthcare Partners and Novo A/S
- 10 Apr 2017 Planned End Date changed from 1 Jul 2018 to 1 Oct 2018.